Q1 2021

Filed May 14, 2021 · 10-Q · 44 days after period end · 0001564590-21-028014

Q1 2021 · 10-Q

Revenue—

Net Income

-$7.15M

N/M vs Q1 2020

EPS Diluted

-$0.51

N/M vs Q1 2020

Operating Income-$7,202,000N/M

Operating Cash Flow-$5,827,000N/M

Same quarter

Metric	Q1 2021	Q1 2020	Q1 2019	Q1 2018
Revenue	—	$8.07M	—	—
Net Income	-$7.15M	$1.75M	-$6.14M	-$10.67M
EPS Diluted	-$0.51	$0.25	-$2.54	-$5.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR